**** OTCQB-IMDS IS GAINING GROUND HERE! ****

SteroidStocks Newsletter

Do your home work and always make sure you speak with your registered advisor before you make any decision.

**** OTCQB:IMDS IS GAINING GROUND HERE! ****

[1]www.steroidstocks.com Recently, [2]I[3]maging Diagnostic Systems, Inc.[4] – ([5]OTCQB:IMDS) announced [6]the CTLM is a New and Unique Imaging Technology Best Described as `Diffuse Optical Tomography` (DOT) Imaging Diagnostic Systems, Inc., (IDSI) ([7]OTCQB:IMDS) – a pioneer in optical breast imaging announced that it has received notification from the Food and Drug Administration (FDA) that the review of the company`s Section 510(k) pre-market notification application of its CTLM system has been completed and categorized as a Class III device requiring a Premarket Approval application.

The FDA determined that the CTLM device is not substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, or to any device which has been reclassified into a class I (General Controls) or class II (Special Controls) or to any device found to be substantially equivalent through the 510 (k) process.

The CTLM system is a laser based breast imaging system intended to provide the physician with physiological and clinical information non-invasively and without the use of ionizing radiation. The patient is positioned in the prone position comfortably on the scanning bed. The laser beam sweeps 360 degrees starting at the chest wall moving forward until the entire breast is scanned.

The CTLM features 3-dimensional and Multi-planar views that display the distribution of blood supply within the vasculature structures of the breast.

This information when interpreted by a trained radiologist can be useful in diagnostic determination.

The CTLM system has received certification and licenses to sell internationally European CE marking, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification. The company`s traditional 510(k) application is pending review from the Food and Drug Administration for marketing clearance in the United States.

For more information visit [8]www.imds.com.

********************

DO YOUR HOMEWORK AND ALWAYS MAKE SURE YOU SPEAK WITH YOUR REGISTERED INVESTMENT ADVISOR BEFORE YOU MAKE ANY DECISION! The SteroidStocks Team [9]http://www.steroidstocks.com/disclaimer/

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.

*****************

*

Make sure you always do your own research and consult with your own financial professional The disclaimer is to be read and fully understood before using our site, or joining our email list.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. SteroidStocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. The owners of SteroidStocks.com have been paid $5,000 by Imaging Diagnostic Systems, Inc. for coverage on IMDS. All information on featured companies is provided by the companies profiled, or is available from public sources and SteroidStocks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. SteroidStocks.com or any of its affiliates are not registered investment advisors or broker dealers. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead, SteroidStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks.

References 1. http://www.steroidstocks.com/

2. http://www.imds.com/

3. http://www.imds.com/

4. http://www.imds.com/

5. http://www.imds.com/

6. http://finance.yahoo.com/news/The-CTLM-is-a-New-and-Unique-bw-1515048836.htmlx=0&.v=1 7. http://www.imds.com/

8. http://www.imds.com/

9. http://www.steroidstocks.com/disclaimer/

This message was sent to from:

Webmaster | 1 Grove St. STE 217 | Pittsford, NY 14534